KR100661973B1 - 6,11 바이사이클릭 에리스로마이신 유도체 - Google Patents

6,11 바이사이클릭 에리스로마이신 유도체 Download PDF

Info

Publication number
KR100661973B1
KR100661973B1 KR1020047018367A KR20047018367A KR100661973B1 KR 100661973 B1 KR100661973 B1 KR 100661973B1 KR 1020047018367 A KR1020047018367 A KR 1020047018367A KR 20047018367 A KR20047018367 A KR 20047018367A KR 100661973 B1 KR100661973 B1 KR 100661973B1
Authority
KR
South Korea
Prior art keywords
formula
aryl
heteroaryl
compound
attached
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047018367A
Other languages
English (en)
Korean (ko)
Other versions
KR20050003454A (ko
Inventor
야트 선 오르
구오치앙 왕
리 탐 판
데치앙 니우
야오-링 쿠이
엔하 후우 보
제이 주드손 파머
잉 호우
Original Assignee
이난타 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이난타 파마슈티칼스, 인코포레이티드 filed Critical 이난타 파마슈티칼스, 인코포레이티드
Priority claimed from PCT/US2003/014914 external-priority patent/WO2003095466A1/en
Publication of KR20050003454A publication Critical patent/KR20050003454A/ko
Application granted granted Critical
Publication of KR100661973B1 publication Critical patent/KR100661973B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020047018367A 2002-05-13 2003-05-13 6,11 바이사이클릭 에리스로마이신 유도체 Expired - Fee Related KR100661973B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US???? 2000-01-12
US14439602A 2002-05-13 2002-05-13
US10/144,396 2002-05-13
PCT/US2003/014914 WO2003095466A1 (en) 2002-05-13 2003-05-13 6,11 bicyclic erythromycin derivatives
US10/436,622 US7129221B2 (en) 2002-05-13 2003-05-13 6,11-bicyclic erythromycin derivatives

Publications (2)

Publication Number Publication Date
KR20050003454A KR20050003454A (ko) 2005-01-10
KR100661973B1 true KR100661973B1 (ko) 2006-12-28

Family

ID=34067652

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047018367A Expired - Fee Related KR100661973B1 (ko) 2002-05-13 2003-05-13 6,11 바이사이클릭 에리스로마이신 유도체

Country Status (6)

Country Link
US (1) US7129221B2 (enExample)
EP (1) EP1509538A1 (enExample)
JP (1) JP2005536465A (enExample)
KR (1) KR100661973B1 (enExample)
CN (1) CN1659178A (enExample)
NZ (1) NZ536402A (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841664B2 (en) * 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US7135573B2 (en) * 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
TW200420573A (en) * 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
AU2004217919A1 (en) * 2003-03-05 2004-09-16 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using the same
WO2005042554A1 (en) * 2003-10-30 2005-05-12 Rib-X Pharmaceuticals, Inc. Bifunctional macrolide heterocyclic compounds and methods of making and using the same
US20070270357A1 (en) * 2003-11-18 2007-11-22 Farmer Jay J Bifunctional Macrolide Heterocyclic Compounds and Methods of Making and Using the Same
US7414030B2 (en) * 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
WO2005070113A2 (en) * 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
EP1723159B1 (en) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US20060058247A1 (en) * 2004-09-16 2006-03-16 Yujiro Hata Methods and compositions for treating cystic fibrosis
CA2598139A1 (en) * 2005-02-21 2006-08-24 Alpharma Aps Method for the production of macrolides
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
US8273720B2 (en) * 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
US8354383B2 (en) * 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
EP2203435B1 (en) * 2007-09-17 2018-07-18 Enanta Pharmaceuticals, Inc. 6, 11-bridged biaryl macrolides
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
WO2009137787A1 (en) 2008-05-09 2009-11-12 Enanta Pharmaceuticals, Inc. Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives
WO2009137739A1 (en) * 2008-05-09 2009-11-12 Enanta Pharmaceuticals, Inc. Processes for the preparation of o-[5-[4-amino-thiazol-2-yl]-pyridin-2-ylmethyl]-hydroxylamine
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
WO2010096051A1 (en) * 2009-02-18 2010-08-26 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl amide macrolide derivatives
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN116947687B (zh) * 2022-04-14 2025-07-18 帕潘纳(北京)科技有限公司 吡唑类除草剂中间体及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
EP0559896B1 (en) 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
ATE135707T1 (de) 1992-04-22 1996-04-15 Taisho Pharmaceutical Co Ltd 5-0-desosaminylerythronolid a derivate
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2738571B1 (fr) 1995-09-11 1997-10-17 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-0-methyl- erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
UA51730C2 (uk) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
CO4990972A1 (es) 1997-10-29 2000-12-26 Abbott Lab Derivados de eritromicina en puente 6,11
US6124269A (en) 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives
US6046171A (en) 1997-10-29 2000-04-04 Abbott Laboratories 6,11-bridged erythromycin derivatives
CA2370743A1 (en) 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
US6878691B2 (en) * 2002-05-13 2005-04-12 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives

Also Published As

Publication number Publication date
US20040053861A1 (en) 2004-03-18
KR20050003454A (ko) 2005-01-10
JP2005536465A (ja) 2005-12-02
NZ536402A (en) 2006-08-31
CN1659178A (zh) 2005-08-24
EP1509538A1 (en) 2005-03-02
US7129221B2 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
KR100661973B1 (ko) 6,11 바이사이클릭 에리스로마이신 유도체
KR100687956B1 (ko) 6-11 비시클릭 케토리드 유도체
JP3821826B2 (ja) ６−１１二環式ケトライド誘導体
ES2218604T3 (es) Derivados triciclicos de eritromicina.
ES2203800T3 (es) Derivados de 3-descladinosa-2, 3-anhidroeritromicina.
AU2003229037B8 (en) 6,11 bicyclic erythromycin derivatives
AU2003239403A2 (en) 6-11 bicyclic ketolide derivatives
KR100924610B1 (ko) 3,6-비시클롤리드
CN101166749B (zh) 6-11桥联的肟乙基琥珀酸红霉素酯衍生物
ES2208334T3 (es) Derivados cetolida de 6-0 carbamato.
US7312201B2 (en) Tetracyclic bicyclolides
US6765016B1 (en) Bicyclic ketolide derivatives
US20040254126A1 (en) 11-12 Bicyclic erythromycin derivatives
ES2254389T3 (es) Agentes anti-infecciosos utiles contra cepas bacterianas resistntes a multiples farmacos.
CN102088848B (zh) 6,11-双环类的9-羟基衍生物的抗菌活性
US6790835B1 (en) Bicyclic macrolide derivatives
WO2008061189A1 (en) C-9 alkenylidine bridged macrolides
WO2004108745A2 (en) 11-12 bicyclic erythromycin derivatives
MX2007013730A (es) Derivados de eritromicina oxima con puente 6-11.
HK1074447B (en) 6-11 bicyclic ketolide derivatives
WO2007115278A2 (en) 3,6,11-tricyclolide

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20121207

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20131204

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20141205

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20151204

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20161123

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171221

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000